Is INmune Bio Inc (INMB) overvalued? · rev $14.0K
INmune Bio Inc (INMB) is a biotechnology company listed on US.
This page asks whether INmune Bio Inc (INMB) looks expensive on cached numbers — not a short thesis.
Latest reported INMB revenue for 2024-12-31 was $14.0K. Net income was -$42.1M. Revenue was down 91.0% from 2023-12-31 to 2024-12-31. INMB currently screens at market cap $33.5M.
INMB currently screens at market cap $33.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next INMB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the INMB stock page for the full model, not this heading.
Not investment advice.